Roche
Committed to innovation and profitable growth

Severin Schwan, CEO Roche Group

New York, May 2012
Roche strategy

*Focused on medically differentiated therapies*
2011: Strong progression of pipeline
17 successful late-stage clinical trials

- Zelboraf
- Erivedge
- pertuzumab
- Lucentis
- Herceptin sc
- Avastin OC
- Actemra
- MetMAB
- dalcetrapib
- Tarceva
- Lucentis
- T-DM1
- lebrikizumab
- Lucentis
- Actemra sc
- GA101
- Actemra
- Erivedge
- MetMAB
- lebrikizumab
- Lucentis
- Actemra sc
- GA101

Positive trials
Strong progression of pipeline
5 successful late-stage clinical trials to date

- **Avastin**
  - TML

- **Herceptin sc**
  - HANNAH

- **Actemra**
  - CHERISH

- **dalcetrapib**
  - dal-OUTCOME

- **Actemra**
  - ADECTA

- **T-DM1**
  - EMILIA

Positive trials
We Innovate Healthcare